摘要
目的观察温阳利尿治疗肝硬化腹水预后效果。方法从2016年12月—2017年10月期间于本院接收并治疗的肝硬化腹水患者中抽取78例为研究对象,采用信封随机法平均分为常规组和试验组2组,每组各39例,给予常规组患者常规抗炎护肝利尿,补白蛋白血浆治疗,试验组患者采用温阳利尿治疗。分析两组患者不同治疗后临床有效率的差异性。结果治疗后,试验组临床总有效率为92.31%,高于常规组,差异有统计学意义(P<0.05)。结论相比常规西医药物注射用促肝细胞生长素和呋塞米片治疗而言,温阳利尿治疗肝硬化腹水预后效果更加显著,可明显提高临床总有效率。
Objective To observe the prognostic effect of Wenyang diuretic therapy on cirrhotic ascites.Methods 78 patients with ascites due to cirrhosis received and treated in our hospital from December 2016 to October 2017 were divided into two groups by envelope random method.Each group consisted of 39 patients.The patients in the conventional group were given routine anti-inflammation,liver protection and diuresis,and albumin plasma supplementation therapy.The experimental group was given Wenyangli.Urine therapy.The difference of clinical efficacy between the two groups after different treatments was analyzed.Results After treatment,the total clinical effective rate of the experimental group was 92.31%,which was higher than that of the conventional group(P<0.05).Conclusion Compared with conventional western medicine injection of hepatocyte growth promoting factor and furosemide tablets,Wenyang diuretic treatment of ascites of liver cirrhosis has a more significant prognostic effect,which can significantly improve the total clinical efficiency.
作者
舒治娥
SHU Zhi'e(Department of Liver and Gallbladder,Xiangyang Hospital of Traditional Chinese Medicine,Xiangyang Hubei 441000,China)
出处
《中国继续医学教育》
2019年第27期145-146,共2页
China Continuing Medical Education
关键词
温阳利尿
肝硬化腹水
肝细胞生长素
呋塞米
预后效果
临床有效率
Wenyang diuresis
cirrhotic ascites
hepatocyte growth factor
furosemide
prognostic effect
clinical efficiency